摘要:
Provided is a polypeptide having FGF2 activity and improved temperature stability and protease resistance. The polypeptide includes at least one substitution selected from a substitution of aspartic acid (D) with glutamic acid (E) at position 28, a substitution of cysteine (C) with isoleucine (I) or leucine (L) at position 78, or a substitution of cysteine (C) with isoleucine (I) or tryptophan (W) at position 96 in SEQ ID NO: 1.
摘要:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
摘要:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
摘要:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
摘要:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
摘要:
Provided is a polypeptide having FGF2 activity and improved temperature stability and protease resistance. The polypeptide includes at least one substitution selected from a substitution of aspartic acid (D) with glutamic acid (E) at position 28, a substitution of cysteine (C) with isoleucine (I) or leucine (L) at position 78, or a substitution of cysteine (C) with isoleucine (I) or tryptophan (VV) at position 96 in SEQ ID NO: 1.
摘要:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
摘要:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.